Education for your patients
Novo Nordisk helps support your patients with resources and tools for success, right from the start. Educational materials are available to download, share, or for delivery to your office.
Education for your patients
Novo Nordisk helps support your patients with resources and tools for success, right from the start. Educational materials are available to download, share, or for delivery to your office.
Share these resources with your patients
Materials available through your Novo Nordisk Representative
The following items are available by contacting your representative:
Patient Welcome Kit
This kit is designed to help patients get started with Rebinyn®. It includes educational resources, such as a Quick Start Guide, Infusion Logbook, a calendar, and a tourniquet—all in a zippered carrying bag.
Travel Case
This portable, reusable travel case makes it possible for your patients to store supplies at home or while traveling.
To request a welcome kit or a travel case for your patient, please contact your representative.
Education for you
Novo Nordisk provides educational materials for professionals who treat patients with hemophilia B.
Patient advocacy groups
Hemophilia Federation of America (HFA)
Connecting people affected by bleeding disorders to others in their community, while advocating for the development of safe, affordable treatment options. Get more info at hemophiliafed.org
National Hemophilia Foundation (NHF)
The largest nonprofit organization dedicated to education, advocacy, and research of inheritable bleeding disorders. Direct patients to find resources at hemophilia.org
World Federation of Hemophilia (WFH)
Committed to improving and sustaining excellent care for people with bleeding disorders across the world. Help patients learn more about the WFH by sending them to wfh.org
Coalition for Hemophilia B
The Coalition for Hemophilia B aims to make quality of life the focal point of treatment for individuals with hemophilia B in the 21st century. For more information, send patients to hemob.org
Selected Important Safety Information for Rebinyn®
Contraindications
- Rebinyn® is contraindicated in patients with a known hypersensitivity to Rebinyn® or its components, including hamster proteins.
Warnings and Precautions
Hypersensitivity reactions, including anaphylaxis, may occur. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic or anaphylactic type reactions occur and initiate appropriate treatment.
Indications and Usage
Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B for on demand treatment and control of bleeding episodes and perioperative management of bleeding.
Limitations of Use: Rebinyn® is not indicated for routine prophylaxis or for immune tolerance induction in patients with hemophilia B.
Important Safety Information
Contraindications
- Rebinyn® is contraindicated in patients with a known hypersensitivity to Rebinyn® or its components, including hamster proteins.
Warnings and Precautions
- Hypersensitivity reactions, including anaphylaxis, may occur. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic or anaphylactic-type reactions occur and initiate appropriate treatment.
- Development of neutralizing antibodies (inhibitors) to Factor IX may occur. Monitor patients for development of factor IX inhibitors if bleeding is not controlled with the recommended dose of Rebinyn® or if expected Factor IX activity plasma levels are not attained. Factor IX activity assay results may vary with the type of activated partial thromboplastin time reagent used.
- The use of Factor IX-containing products has been associated with thrombotic complications. Monitor for thrombotic and consumptive coagulopathy when administering Rebinyn® to patients with liver disease, post-operatively, to newborn infants, or to patients at risk of thrombosis or disseminated intravascular coagulation (DIC).
- Nephrotic syndrome has been reported following immune tolerance induction therapy with Factor IX products in hemophilia B patients with Factor IX inhibitors, often with a history of allergic reactions to Factor IX. The safety and efficacy of using Rebinyn® for immune tolerance induction have not been established.
Adverse Reactions
- The most common adverse reactions reported in clinical trials (≥1%) were itching and injection site reactions.
- Animals administered repeat doses of Rebinyn® showed accumulation of PEG in the choroid plexus. The potential clinical implications of these animal findings are unknown.
Please click here for Rebinyn® Prescribing Information.